ISA Pharmaceuticals and Scancell enter collaboration agreement for the manufacturing, development and commercialisation of Modi-1 / AMPLIVANT® combination

15 Feb 2018

– AMPLIVANT-Modi-1 conjugate expected to enter clinic in H1 2019

– Collaboration seeks to further leverage Moditope® platform

Leiden, The Netherlands, and Oxford, UK, 15 February, 2018 — ISA Pharmaceuticals B.V. (‘ISA’), a clinical-stage immunotherapy company, and Scancell Holdings plc, (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the treatment of cancer, are pleased to announce that they have entered into a worldwide licensing and collaboration agreement to use ISA’s AMPLIVANT® adjuvant technology for the manufacturing, development and commercialisation of Scancell’s first Moditope® development candidate, Modi-1.  This partnership has the potential to provide a new treatment option for patients with

Read more »